A double-blind, randomized, controlled trial was conducted with the main objective of evaluating if patients with clinical assessment and VExUS reach decongestion faster within a maximum period of 7 days during the hospital stay. Likewise, the study will describe those patients who experience a decrease in serum creatinine (CrS), NT-proBNP at discharge, greater diuretic adjustment, rate of intrahospital readmission, and 30-day mortality.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
80
Patients allocated in the experimental arm will have diuretic dosing adjusted based on ultrasound findings (VExUS Score)
Patients allocated in the experimental arm will have diuretic dosing adjusted based on clinical findings (CCS Score)
Instituto Nacional de Cardiología Ignacio Chávez
Mexico City, Mexico
RECRUITINGDecongestion within 7 days
Assess if the ultrasound guided arm achieves faster decongestion
Time frame: 7 days
Acutely decompensated heart failure readmission rate
Assess which strategy achieves less readmission rate
Time frame: 7 days
Length of hospital stay
Assess which strategy achieves fewer days of hospital stay
Time frame: 7 days
Total diuretic dose within 7 days
Assess which strategy has greater diuretic adjustment
Time frame: 7 days
Number of participants that initiate kidney replacement therapy
Assess which strategy is associated with kidney replacement therapy
Time frame: 30 days
Intrahospital mortality
Assess which strategy achieves less intrahospital mortality
Time frame: 30 days
Days alive out of hospital
Assess which strategy achieves more days alive out of hospital
Time frame: 1 month
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.